Cargando…

Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma

Pleomorphic invasive lobular carcinoma (PILC) is a distinct morphological and biologically aggressive variant of invasive lobular carcinoma (ILC). We hypothesized that was due to de novo activation of PI3K/Akt/mTOR pathway in PILC resulting in higher proliferation rate and markers of cell cycle acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Segar, Jennifer M., Pandey, Ritu, Farr, Kiah J., Nagle, Raymond, LeBeau, Lauren, Gonzalez, Victor J., Chalasani, Pavani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704199/
https://www.ncbi.nlm.nih.gov/pubmed/33299611
http://dx.doi.org/10.1155/2020/8816824
_version_ 1783616773289934848
author Segar, Jennifer M.
Pandey, Ritu
Farr, Kiah J.
Nagle, Raymond
LeBeau, Lauren
Gonzalez, Victor J.
Chalasani, Pavani
author_facet Segar, Jennifer M.
Pandey, Ritu
Farr, Kiah J.
Nagle, Raymond
LeBeau, Lauren
Gonzalez, Victor J.
Chalasani, Pavani
author_sort Segar, Jennifer M.
collection PubMed
description Pleomorphic invasive lobular carcinoma (PILC) is a distinct morphological and biologically aggressive variant of invasive lobular carcinoma (ILC). We hypothesized that was due to de novo activation of PI3K/Akt/mTOR pathway in PILC resulting in higher proliferation rate and markers of cell cycle activation. We identified PILC and ILC tumors and tested for PI3K/Akt/mTOR pathway activation by immunohistochemistry (PTEN and pS6K1) and gene expression analysis (by Nanostring nCounter system). Proliferation index (Ki67) was elevated in 85% of PILCs compared to 20% of ILCs (p < 0.007). PTEN expression was high in all while pS6K1 was high in 8/9 PILCs compared to 3/9 ILCs (p < 0.007). Gene expression analysis shows that PILCs have overexpression of genes involved in cell cycle proliferation, cellular proliferation, DNA damage, and repair genes but no difference in PI3K/Akt/mTOR pathway genes. PILCs are a biologically distinct group of ILC, and clinicopathological characteristics suggest they would have a more clinically aggressive behavior. In addition, our results indicate that PI3k/Akt/mTOR pathway and cell cycle proliferation are activated in majority of these tumors. Further studies are needed to investigate these mechanisms as there are approved therapies available that may benefit PILCs.
format Online
Article
Text
id pubmed-7704199
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-77041992020-12-08 Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma Segar, Jennifer M. Pandey, Ritu Farr, Kiah J. Nagle, Raymond LeBeau, Lauren Gonzalez, Victor J. Chalasani, Pavani Int J Breast Cancer Research Article Pleomorphic invasive lobular carcinoma (PILC) is a distinct morphological and biologically aggressive variant of invasive lobular carcinoma (ILC). We hypothesized that was due to de novo activation of PI3K/Akt/mTOR pathway in PILC resulting in higher proliferation rate and markers of cell cycle activation. We identified PILC and ILC tumors and tested for PI3K/Akt/mTOR pathway activation by immunohistochemistry (PTEN and pS6K1) and gene expression analysis (by Nanostring nCounter system). Proliferation index (Ki67) was elevated in 85% of PILCs compared to 20% of ILCs (p < 0.007). PTEN expression was high in all while pS6K1 was high in 8/9 PILCs compared to 3/9 ILCs (p < 0.007). Gene expression analysis shows that PILCs have overexpression of genes involved in cell cycle proliferation, cellular proliferation, DNA damage, and repair genes but no difference in PI3K/Akt/mTOR pathway genes. PILCs are a biologically distinct group of ILC, and clinicopathological characteristics suggest they would have a more clinically aggressive behavior. In addition, our results indicate that PI3k/Akt/mTOR pathway and cell cycle proliferation are activated in majority of these tumors. Further studies are needed to investigate these mechanisms as there are approved therapies available that may benefit PILCs. Hindawi 2020-11-22 /pmc/articles/PMC7704199/ /pubmed/33299611 http://dx.doi.org/10.1155/2020/8816824 Text en Copyright © 2020 Jennifer M. Segar et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Segar, Jennifer M.
Pandey, Ritu
Farr, Kiah J.
Nagle, Raymond
LeBeau, Lauren
Gonzalez, Victor J.
Chalasani, Pavani
Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma
title Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma
title_full Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma
title_fullStr Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma
title_full_unstemmed Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma
title_short Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma
title_sort clinicopathological and molecular characteristics of pleomorphic invasive lobular carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704199/
https://www.ncbi.nlm.nih.gov/pubmed/33299611
http://dx.doi.org/10.1155/2020/8816824
work_keys_str_mv AT segarjenniferm clinicopathologicalandmolecularcharacteristicsofpleomorphicinvasivelobularcarcinoma
AT pandeyritu clinicopathologicalandmolecularcharacteristicsofpleomorphicinvasivelobularcarcinoma
AT farrkiahj clinicopathologicalandmolecularcharacteristicsofpleomorphicinvasivelobularcarcinoma
AT nagleraymond clinicopathologicalandmolecularcharacteristicsofpleomorphicinvasivelobularcarcinoma
AT lebeaulauren clinicopathologicalandmolecularcharacteristicsofpleomorphicinvasivelobularcarcinoma
AT gonzalezvictorj clinicopathologicalandmolecularcharacteristicsofpleomorphicinvasivelobularcarcinoma
AT chalasanipavani clinicopathologicalandmolecularcharacteristicsofpleomorphicinvasivelobularcarcinoma